ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Leveraged & Inverse ETF Channel
  2. Direxion Launches mRNA Technology ETF, MSGR
Leveraged & Inverse ETF Channel
Share

Direxion Launches mRNA Technology ETF, MSGR

Karrie GordonDec 09, 2021
2021-12-09

Direxion has announced today in a press release the launch of their newest ETF that focuses on the applications and developments of messenger RNA technology, the Direxion mRNA ETF.

The fund looks to capture the growth within the mRNA field by investing in companies that are working to develop and apply mRNA technology. mRNA is a molecule that is largely responsible for protein synthesis in the body and is complementary to strands within DNA. By working to alter mRNA, technologies are able to target specific diseases, helping build the body’s immune response to them.

The technology has most recently been used to create both the Pfizer BioNTech as well as the Moderna COVID vaccines.

“For years, messenger RNA (mRNA) technologies struggled to gain acceptance. The COVID-19 pandemic changed all of that, thanks to the highly effective vaccines developed using mRNA to combat the novel coronavirus and its emerging variants,” said David Mazza, managing director, head of product, Direxion, in the press release.

MSGR seeks to track the BITA Messenger RNA Technology Index, an index that tracks companies in the U.S., Canada, and Europe leading mRNA technology development and application. Mazza explained in a note the importance of a global exposure for the fund: “ETFs focused on nascent and narrow areas of the market can benefit from taking a global approach to identifying companies for inclusion. For example, if MSGR only included companies domiciled in the US, it would miss out on exposure to BioNTech, one of the most important companies involved with mRNA.”

Companies included in the index must either be involved in therapies and the commercialization of mRNA technologies or sister mRNA technologies; be classified as a clinical stage biotechnology company with a focus on mRNA technologies; be a company with a portfolio of active, approved mRNA technology clinical trials; or else have granted, active patents that demonstrate involvement with mRNA.

Many of the companies contained within MSGR aren’t found in any other ETFs. The following is a snapshot of the top 10 holdings for the fund at launch.

Direxion Chart Graph

Image source: Direxion

“MSGR captures companies specifically involved with mRNA technologies that are believed to be at the forefront of fighting the battle against COVID, while also highlighting mRNA’s application to other viruses and diseases, including HIV and Lyme disease,” said Mazza.

MSGR carries an expense ratio of 0.65%.

For more news, information, and strategy, visit the Leveraged & Inverse Channel.


Content continues below advertisement

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X